Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients

Broseta, José Jesús; Rodríguez-Espinosa, Diana; Rodríguez, Néstor; Mosquera, Marı́a del Mar; Marcos, María Ángeles; Egri, Natalia; Pascal, Mariona; Soruco, Erica; Bedini, José Luis; Bayés, Beatriu; Maduell, Francisco

doi:10.1053/j.ajkd.2021.06.002

Cited by 109 publications

(137 citation statements)

References 47 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Our findings of high antibody levels among MHD patients who recovered from COVID-19 correlate with previous studies of vaccinated MHD patients, [4,[8][9] J o u r n a l P r e -p r o o f and in the general population. In addition, a large study found sustained antibody levels in seropositive MHD patients, even without vaccination [10].…”

Section: J O U R N a L P R E -P R O O Fsupporting

confidence: 90%

“…Previous studies reported high rates of early (14-30 days) seroconversion after BNT162b2, exceeding 90%. [2][3][4] While we suspect the lower rates in our study may result from decay of the humoral response over time, we cannot exclude that low antibody levels at 6 months post-vaccination represent weak initial vaccine responses. This distinction may prove critical to clarify when considering additional "booster" vaccine doses.…”

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 81%

See 1 more Smart Citation

Long-term Antibody Response to the BNT162b2 Vaccine Among Maintenance Hemodialysis Patients

Nacasch

Erez

Lishner

et al. 2022

American Journal of Kidney Diseases

View full text Add to dashboard Cite

Section: J O U R N a L P R E -P R O O Fsupporting

confidence: 90%

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 81%

Long-term Antibody Response to the BNT162b2 Vaccine Among Maintenance Hemodialysis Patients

Nacasch

Erez

Lishner

et al. 2022

American Journal of Kidney Diseases

View full text Add to dashboard Cite

“…Current studies have mostly evaluated the effectiveness of vaccines in the form of IgG titers. However, studies involving the cellular responses or human leukocyte antigen are sparse and inconclusive [ 55 , 56 , 57 ]. Further studies should be undertaken to enhance the understanding of immune mechanisms following COVID-19 vaccination in patients with MHD.…”

Section: Effectiveness Of Covid-19 Vaccines In Hemodialysis Patientsmentioning

confidence: 99%

COVID-19 Vaccines in Patients with Maintenance Hemodialysis

Yen

Lin

Chen

et al. 2021

JPM

View full text Add to dashboard Cite

The COVID-19 pandemic has infected more than 180 million people and caused more than 3.95 million deaths worldwide. In addition to personal hygiene, augmented cleaning, social distancing, and isolation, vaccine development and immunization are essential for this highly contagious disease. Patients with maintenance hemodialysis (MHD) have a greater risk of COVID-19 infection owing to their comorbidities, defective immunity, and repeated crowded in-center dialysis settings. However, many patients hesitate to get vaccinated because of their misunderstandings. The Efficacy of COVID-19 vaccination has been intensively discussed in the general population, whereas the data concerning the effectiveness of vaccination in MHD patients are relatively scanty. Nevertheless, those limited publications can provide some valuable information. Overall, lower and more delayed antibody responses following COVID-19 vaccination were observed in patients with MHD than in healthy controls in the settings of different populations, vaccines and dosage, definitions of the immune response, and antibody detection timepoints. Younger age, previous COVID-19 infection, and higher serum albumin level were positively associated with antibody formation, whereas older age and receiving immunosuppressive therapy were unfavorable factors. However, it remains uncertain between the elicited antibodies following vaccination and the genuine protection against COVID-19 infection. Patients with MHD should make their COVID-19 vaccination a priority in addition to other protective measures. More studies focusing on different vaccines, non-humoral immune responses, and risk-benefit analyses are warranted.

show abstract

“…There are few studies that have addressed the cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in HD-patients [ 9 – 13 ]. In the ROMANOV study a decreased cellular response to the BNT162b2 vaccine was found [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients

et al. 2021

View full text Add to dashboard Cite

Background Hemodialysis (HD) patients have an increased risk of acquiring infections due to many health care contacts and may, in addition, have a suboptimal response to vaccination and a high mortality from Covid-19 infection. Methods In 50 HD patients (mean age 69.4 years, 62% men) administration of SARS-CoV-2BNT162b2 mRNA vaccine began in Dec 2020 and the immune response was evaluated 7–15 weeks after the last dose. Levels of Covid-19 (SARS-CoV-2) IgG antibody against the nucleocapsid antigen (anti-N) and the Spike antigen (anti-S) and T-cell reactivity testing against the Spike protein using ELISPOT technology were evaluated. Results Out of 50 patients, anti-S IgG antibodies indicating a vaccine effect or previous Covid-19 infection, were detected in 37 (74%), 5 (10%) had a borderline response and 8 (16%) were negative after two doses of vaccine. T-cell responses were detected in 29 (58%). Of the 37 patients with anti-S antibodies, 25 (68%) had a measurable T-cell response. 2 (40%) out of 5 patients with borderline anti-S and 2 (25%) without anti-S had a concomitant T-cell response. Twenty-seven (54%) had both an antibody and T-cell response. IgG antibodies to anti-N indicating a previous Covid-19 disease were detected in 7 (14%) patients. Conclusions Most HD patients develop a B- and/or T-cell response after vaccination against Covid-19 but approx. 20% had a limited immunological response. T-cell reactivity against Covid-19 was only present in a few of the anti-S antibody negative patients.

show abstract

Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients

Cited by 109 publications

References 47 publications

Long-term Antibody Response to the BNT162b2 Vaccine Among Maintenance Hemodialysis Patients

Long-term Antibody Response to the BNT162b2 Vaccine Among Maintenance Hemodialysis Patients

COVID-19 Vaccines in Patients with Maintenance Hemodialysis

Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients

Contact Info

Product

Resources

About